Kodiak Sciences Dirección

Dirección controles de criterios 2/4

El CEO de Kodiak Sciences' es Victor Perlroth , nombrado en Jun 2009, tiene una permanencia de 13.83 años. compensación anual total es $113.37M, compuesta por 0.6% salario y 99.4% primas, incluidas acciones y opciones de la empresa. posee directamente un 5.06% de las acciones de la empresa, por valor de MX$218.52M. La antigüedad media del equipo directivo y de la junta directiva es de 3.9 años y 4.8 años, respectivamente.

Información clave

Victor Perlroth

Chief Executive Officer (CEO)

US$113.4m

Compensación total

Porcentaje del salario del CEO	0.6%
Permanencia del CEO	13.8yrs
Participación del CEO	5.1%
Permanencia media de la dirección	3.9yrs
Promedio de permanencia en la Junta Directiva	4.8yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Victor Perlroth en comparación con los beneficios de Kodiak Sciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2022	n/a	n/a	-US$334m
Sep 30 2022	n/a	n/a	-US$357m
Jun 30 2022	n/a	n/a	-US$347m
Mar 31 2022	n/a	n/a	-US$312m
Dec 31 2021	US$113m	US$655k	-US$267m
Sep 30 2021	n/a	n/a	-US$220m
Jun 30 2021	n/a	n/a	-US$189m
Mar 31 2021	n/a	n/a	-US$159m
Dec 31 2020	US$9m	US$591k	-US$133m
Sep 30 2020	n/a	n/a	-US$102m
Jun 30 2020	n/a	n/a	-US$78m
Mar 31 2020	n/a	n/a	-US$64m
Dec 31 2019	US$18m	US$526k	-US$47m
Sep 30 2019	n/a	n/a	-US$46m
Jun 30 2019	n/a	n/a	-US$44m
Mar 31 2019	n/a	n/a	-US$41m
Dec 31 2018	US$6m	US$428k	-US$41m
Sep 30 2018	n/a	n/a	-US$38m
Jun 30 2018	n/a	n/a	-US$32m
Mar 31 2018	n/a	n/a	-US$31m
Dec 31 2017	US$824k	US$388k	-US$28m

Compensación vs. Mercado: La compensación total de Victor($USD113.37M) está por encima de la media de empresas de tamaño similar en el mercado MX ($USD300.43K).

Compensación vs. Ingresos: La compensación de Victor ha aumentado mientras la empresa no es rentable.

CEO

Victor Perlroth (49 yo)

13.8yrs

Permanencia

US$113,371,207

Compensación

Dr. Victor Perlroth, M.D co-founded Kodiak Sciences Inc. in 2009 and serves as its co-founder, Chairman, President and Chief Executive Officer. Dr. Perlroth serves as Chief Executive officer since June 200...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Victor Perlroth	Co-Founder	13.8yrs	US$113.37m	5.06% $ 218.5m
John Borgeson	Senior VP	8.8yrs	US$27.87m	0.33% $ 14.4m
Jason Ehrlich	Chief Medical Officer & Chief Development Officer	4.6yrs	US$27.95m	0.11% $ 4.7m
Michael Louie	Senior VP of Digital Transformation & Chief Information Officer	1.2yrs	sin datos	sin datos
Hong Liang	Senior Vice President of Discovery Medicine	5.5yrs	US$321.91k	sin datos
Stephen Raillard	Senior Vice President of Chemical Development & Manufacturing	less than a year	sin datos	sin datos
Almas Qudrat	Senior Vice President of Quality Operations	3.3yrs	sin datos	sin datos
J. Velazquez-Martin	Senior Vice President of Clinical Research & Translational Medicine	less than a year	sin datos	sin datos

3.9yrs

Permanencia media

49.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de KOD * se considera experimentado (3.9 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Victor Perlroth	Co-Founder	13.8yrs	US$113.37m	5.06% $ 218.5m
Robert Profusek	Lead Independent Director	4.8yrs	US$471.07k	0.019% $ 829.4k
Felix Baker	Independent Director	7.6yrs	US$389.82k	0% $ 0
Richard Levy	Independent Director	4.8yrs	US$436.07k	0.0019% $ 82.9k
Bassil Dahiyat	Independent Director	4.8yrs	US$442.18k	0% $ 0
Charles Bancroft	Independent Director	3yrs	US$460.97k	0.050% $ 2.2m
David Boyer	Scientific Advisor	no data	sin datos	sin datos
Michael IP	Scientific Advisor	no data	sin datos	sin datos
Sunil Patel	Scientific Advisor	no data	sin datos	sin datos
David Brown	Scientific Advisor	no data	sin datos	sin datos
Carl Regillo	Scientific Advisor	no data	sin datos	sin datos
Pravin Dugel	Scientific Advisor	no data	sin datos	sin datos

4.8yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de KOD * se considera experimentada (4.8 años de antigüedad promedio).

Kodiak Sciences Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Kodiak Sciences Inc., Annual General Meeting, Jun 04, 2024

Jason Ehrlich, M.D., Ph.D., Informs Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Jason Ehrlich, M.D., Ph.D., Informes Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Co-Founder recently sold Mex$251m worth of stock

Recent updates

Kodiak Sciences Inc. Announces Treatment of First Patients in Phase 3 GLOW2 Study of Tarcocimab Tedromer in Diabetic Retinopathy

Kodiak Sciences Inc. Announces Data at ARVO 2024 Highlight Depth of Early and Late-Phase Retina Pipeline including Advancements with High Drug-Antibody-Ratio Therapeutics Built on Kodiak's Antibody Biopolymer Conjugate (ABC) Platform

Kodiak Sciences Inc., Annual General Meeting, Jun 04, 2024

Kodiak Sciences Inc. to Report Q4, 2023 Results on Mar 28, 2024

Kodiak Sciences Inc. Announces Presentation of Primary Endpoint Data from Tarcocimab Tedromer Phase 3 Glow Study in Patients with Diabetic Retinopathy at American Academy of Ophthalmology Annual Meeting

Kokak Sciences Inc. Announces Top-Line, One-Year Results for Its ABC Platform Based Investigational Therapy Tarcocimab Tedromer 5 Mg from the Pivotal Beacon Study

Jason Ehrlich, M.D., Ph.D., Informs Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Jason Ehrlich, M.D., Ph.D., Informes Kodiak Sciences Inc. of His Resignation as Chief Medical Officer and Chief Development Officer, Effective August 25, 2023

Kodiak Sciences Announces Topline Results from its Phase 3 Studies of Tarcocimab Tedromer in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema and Provides Update on Tarcocimab Development Program

Kodiak Sciences Reports Positive Topline Results from Beacon Phase 3 Study of Tarcocimab Tedromer (Ksi-301) in Patients with Retinal Vein Occlusion

Kodiak Sciences Inc. Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic Retinopathy

Kodiak Sciences Inc.(NasdaqGM:KOD) dropped from Russell 2000 Growth Index

Co-Founder recently sold Mex$251m worth of stock

Kodiak Sciences Inc. Announces Top-Line Results from Its Initial Phase 2B/3 Study of KSI-301 in Patients with Neovascular Age-Related Macular Degeneration

Kodiak Sciences Inc. Completes Enrollment in Gleam and Glimmer Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular Edema

Kodiak Sciences Inc. Completes Enrollment in BEACON Phase 3 Clinical Trial of KSI-301 in Patients with Retinal Vein Occlusion

Forecast to breakeven in 2025

Forecast to breakeven in 2024

Kodiak Sciences Inc. Announces 1-Year Durability, Efficacy and Safety Data from Ongoing Phase 1B Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration, Diabetic Macular Edema and Retinal Vein Occlusion at the Angiogenesis, Exudation and Degeneration 2021 Annual Meeting

Kodiak Sciences Completes Enrollment of DAZZLE Phase 2b/3 Pivotal Study of KSI-301 in Patients with Wet Age-Related Macular Degeneration

Kodiak Sciences Inc. to Report Q3, 2020 Results on Nov 09, 2020

Kodiak Sciences Inc. Treats First Patients in Three Phase 3 Studies of KSI-301 - Two Studies in Diabetic Macular Edema and One Study in Macular Edema Due to Retinal Vein Occlusion

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad